STRIDE Outcomes by Sexl

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

5 More presentations in this session

Presentation thumbnail

CONFIDENCE: Results by KDIGO risk category

Doctor M. Vaduganathan (Boston, US)

Presentation thumbnail

SGLT2i and AF

Doctor J. Sedighi (Giessen, DE)

Presentation thumbnail

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

Professor M. Mamas (Keele, GB)

Presentation thumbnail

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Ms L. Wilson (US)

Presentation thumbnail

Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction

Doctor N. Kruger (Boston, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age

Congress Session

Late-Breaking Clinical Science: cardiometabolic medicine

Congress Session

Cardiovascular and limb outcomes in peripheral artery disease

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources